Latest Regulatory News

Cynata Therapeutics has opened a fully underwritten $913,000 entitlement offer to fund adviser, director and consultant fees, offer costs and working capital. Eligible shareholders can buy three new shares for every eight held, with free options attached.

Vysarn delivered another year of rapid earnings growth, with revenue rising 31% and net profit after tax climbing 41% to $15.11 million. The bigger test now is whether its $65.3 million capital raise and Welltech acquisition can turn a growing collection of water businesses into a genuinely national platform.

InFocus Group has signed its first Codexa ROW customer, with a conditional agreement that could deliver at least USD 2.4 million over 24 months. The company must first build and validate a prediction markets module, secure regulatory readiness and complete the customer's licensing and SPV arrangements.

Firebrick Pharma has secured Philippine marketing approval for Nasodine Nasal Spray as an over-the-counter antiseptic, opening a potential launch in the 116 million-person market from early 2027. The approval remains subject to post-approval documentation and future revalidation.

Dusk Group has carried its FY26 momentum into the new financial year, with like-for-like sales up 7.2% in the first 15 weeks despite operating six fewer stores. The home-fragrance retailer is now preparing a tightly controlled South African launch while an unresolved ACCC court case remains a material complication.

Alcoa delivered a $483 million third-quarter profit and its sixth consecutive quarter of higher aluminium production, while South32 shareholders approved the company’s planned upstream asset acquisition. The deal remains targeted for completion in the first half of 2027, with $2.6 billion of acquisition financing now raised.

Santana Minerals has moved the Bendigo-Ophir Gold Project closer to development, with a draft Fast-track Approvals decision expected in the December quarter and a competitive project debt process now underway. Strong Rise and Shine drilling and an A$179.7 million quarter-end cash balance provide further support, although construction remains conditional on approvals, financing and a final investment decision.

SkyCity has signed a conditional agreement to sell The Grand Hotel and its business assets for $221 million, converting a previously proposed transaction into a binding deal. The proceeds are intended to repay debt, although completion still depends on Overseas Investment Office consent and other conditions.

Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.

Kelly Partners Group Holdings has secured conditional ASX approval to delist, clearing a regulatory milestone in its proposed move to Nasdaq. The plan still depends on shareholder approval and the US listing process, with no effective delisting date set.

Fletcher Building has secured Fast Track approval to expand and deepen its Hunua Quarry, opening access to approximately 225 million tonnes of greywacke. The consent could support more than 50 years of quarry operations, although the announcement does not quantify development costs, timing or financial returns.

Kingsrose Mining has secured the key Finnish approvals needed to advance drilling at Area 6 of its Penikat project, with a January 2027 start still targeted. Appeals remain possible until 20 November, but a separate enforcement order could allow restricted drilling while any challenge is heard.